Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive $300 million from an early settlement of some prepaid shares of Cencora ...

Our proprietary system currently recommends Cencora (COR) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...

It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...